Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Muscarinic antagonists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Muscarinic antagonists. Displaying page 1 of 1.
    EudraCT Number: 2010-020440-35 Sponsor Protocol Number: D589BC00004 Start Date*: 2011-09-16
    Sponsor Name:Imperial College London
    Full Title: GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort®/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005615-17 Sponsor Protocol Number: RPL554-008-2014 Start Date*: 2015-04-22
    Sponsor Name:Verona Pharma plc
    Full Title: A Phase II, randomised, double blind, placebo controlled, seven way crossover study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser on lu...
    Medical condition: Patients with chronic asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003594-99 Sponsor Protocol Number: 2013RC09 Start Date*: 2013-11-27
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: Proof of Concept Evaluation of Drug-Device Interaction with aclidinium bromide via Genuair® and tiotropium bromide via HandiHaler® in COPD using Impulse Oscillometry
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003920-35 Sponsor Protocol Number: CQAW039B2201 Start Date*: 2019-06-12
    Sponsor Name:Novartis Farmacéutica
    Full Title: A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via a once daily chewable tablet in children aged 6 to <12 years wi...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002292-18 Sponsor Protocol Number: 7569 Start Date*: 2019-05-24
    Sponsor Name:University Hospital of Montpellier
    Full Title: CT air-trapping characterization for the early identification of Benralizumab responders among eosinophilic asthma patients
    Medical condition: The study population corresponds to severe eosinophilic asthma patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003079-69 Sponsor Protocol Number: D5180C00009 Start Date*: 2018-04-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid ...
    Medical condition: Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001040-35 Sponsor Protocol Number: D3250C00045 Start Date*: 2017-08-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled ...
    Medical condition: severe uncontrolled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049106 Asthma chronic LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) FR (Completed) BE (Completed) SE (Completed) NL (Completed) AT (Completed) ES (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005184-27 Sponsor Protocol Number: 49095397OPD2001 Start Date*: 2013-08-20
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ-49095397 (RV568) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease.
    Medical condition: Moderate to Severe Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) HU (Completed) CZ (Completed) NL (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-003005-30 Sponsor Protocol Number: AR-DEX-22-03 Start Date*: 2023-06-28
    Sponsor Name:Areteia Therapeutics, Inc.
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinop...
    Medical condition: Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002517-35 Sponsor Protocol Number: V00162PI2024A Start Date*: 2013-09-05
    Sponsor Name:Pierre Fabre Médicament/Institut de Recherche Pierre Fabre
    Full Title: Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2007-001051-19 Sponsor Protocol Number: CQAB149B2217 Start Date*: 2007-07-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic...
    Medical condition: COPD (chronic Obstructive Pulmonary Disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000643-95 Sponsor Protocol Number: CNVA237A2206 Start Date*: 2007-06-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-003004-33 Sponsor Protocol Number: AR-DEX-22-01 Start Date*: 2023-04-26
    Sponsor Name:Areteia Therapeutics, Inc.
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe ...
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:48:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA